Market Access

As FDA fast-tracks GLP-1 treatments under its new pilot National Priority Voucher program, WeightWatchers prepares to position itself to compete in the fast-evolving weight-loss drug market driven by affordability and accessibility.

Launching next year, the new CMS Innovation Center initiative—known as the GENEROUS Model—aims to align Medicaid drug prices with global standards, reduce prescription spending, and strengthen the program’s long-term sustainability through fairer state purchasing and transparent pricing rules.

As the three models converge, expect a bigger role for sales reps, minimal impact on incentive compensation, and a boon to the healthcare system.

The formula for bridging scientific advancement with operational flexibility in boosting access to cell and gene therapies.

At HLTH 2025, the entrepreneur announced a collaboration between Cost Plus Drugs and President Trump’s TrumpRx platform aimed at improving transparency, reducing drug costs, and reshaping how Americans access their prescriptions.

An analysis of pricing data for 12 high-revenue drugs from Medicare Part B and Part D compares US wholesale acquisition costs with the lowest prices in reference countries under the most-favored nation model.

Amid converging pharma pricing trends, such as those triggered by the Inflation Reduction Act, companies must adopt novel operational practices and strategic approaches in line with new parameters for success across a product’s lifecycle.

Q&A with Harry Totonis, CEO and chairman of ConnectiveRx, on embracing change and seeking better solutions amid today’s challenging playing field for patient access.

As timelines change, medical affairs teams must adjust their skillsets.

While the MFN executive order targets drug companies for drug prices, Peter Rubin discusses how health plans also play a large role in this area.

Most Favored Nation drug pricing proposal aims to tie US medicine costs to lower European rates, but experts warn this approach could restrict patient access to lifesaving treatments, slow innovation, and jeopardize future drug development by importing flawed foreign price-control models.

Jason O’Neill, author of 'The Secrets of Successful Drug Launches' and former Dendreon CEO, continues his conversation about launch failures, this time detailing unrealistic launch forecasts, underinvestment in preparing the market, and a lack of valuable follow-on instructions can hurt a launch.

Peter Rubin discusses how effective President Trump’s executive order could actually be against the factors that dictate drug pricing.

The arrival of GLP-1 receptor agonists and dual agonists has delivered unprecedented efficacy, reframed obesity as a chronic disease, and sparked an industry gold rush.

The HOSP Alliance leader discusses the role of specialty pharmacies in the current market.

Outlining the key touchpoints for embracing change and opportunity in the “messy, tough—and fun” R&D-to-commercial transition journey.

Useful tips and parallels for staying in the game following a complete response letter.

Key areas may offer useful strategies for introducing innovative products to market.

The draft assessment finds that the popular weight loss drugs are costly but worth the price tag, while also urging for broader coverage and policy solutions.

Pushing for access wins in quickly evolving market and digital health landscapes.

Challenging six misconceptions that have characterized product strategies in Central and Eastern European markets.

Webinar Date/Time: Mon, Jul 28, 2025 11:00 AM EDT

While the growing oncology pipeline offers tremendous potential, the path from clinical development through to commercial launch and patient administration is complex and lined with challenges that can impact product success and access.

Q&A with Model N's Michael Grosberg drills deeper into the new US drug pricing directives, including challenges in implementation, the potential unintended consequences, and how these actions could spark the shift to outcomes-based contracting in healthcare.

Not lost in the mix of June's wide-ranging coverage in Pharmaceutical Executive is an honest take on what guest thought leaders argue is “undoubtedly” the hardest job in biopharma.